Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bretylium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bretylium SCHEMBL2638448 | 0.84 | MAPK1 (0.58) | MAPK1LMNACYP3A4CYP2D6THPO | |
| Bretylium SCHEMBL29688247 | 0.78 | LMNA (0.65) | MAPK1LMNACYP3A4CYP2D6THPO | |
| Bretylium SCHEMBL542733 | 0.78 | LMNA (0.65) | MAPK1LMNACYP3A4CYP2D6THPO | |
| Bretylium SCHEMBL15438 | 0.78 | LMNA (0.65) | MAPK1LMNACYP3A4CYP2D6THPO | |
| SCHEMBL11670181 | 0.77 | DNM1 (0.48) | MAPK1BBOX1DNM1MEN1KMT2A | |
| Bretylium SCHEMBL6227453 | 0.77 | LMNA (0.63) | MAPK1LMNACYP3A4CYP2D6THPO | |
| Bretylium SCHEMBL6314565 | 0.77 | LMNA (0.63) | MAPK1LMNACYP3A4CYP2D6THPO | |
| Bretylium SCHEMBL16398024 | 0.77 | LMNA (0.63) | MAPK1LMNACYP3A4CYP2D6THPO | |
| Bretylium SCHEMBL29387750 | 0.77 | LMNA (0.63) | MAPK1LMNACYP3A4CYP2D6THPO | |
| Bretylium SCHEMBL40898 | 0.76 | LMNA (1.00) | MAPK1LMNACYP3A4CYP2D6THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4750278-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1140054-B1 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | BACANER MARVIN B (US) | 2005-03-16 | — | — | EP | claimed |
| US-6482811-B1 | Bretylium compositions and kits, and their use in preventing and treating cardio-vascular conditions | BACANER MARVIN B (US) | 2002-11-19 | — | — | US | claimed |
| EP-1140054-A2 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | Bacaner, Marvin B. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040232-A2 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | BACANER MARVIN B (US) | 2000-07-13 | — | — | WO | claimed |
| US-6884792-B2 | Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | BACANER MARVIN B (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1140054-B1 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | BACANER MARVIN B (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030119794-A1 | Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | BACANER MARVIN B (US) | 2003-06-26 | — | — | US | disclosed |
| US-6482811-B1 | Bretylium compositions and kits, and their use in preventing and treating cardio-vascular conditions | BACANER MARVIN B (US) | 2002-11-19 | — | — | US | disclosed |
| EP-1140054-A2 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | Bacaner, Marvin B. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040232-A2 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | BACANER MARVIN B (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119794-A1 | Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | TNNT2, TNNI3, FABP3 | MAPK1 3234/4885LMNA 832/4885CYP3A4 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.